Genentech MA29895: An exploritory multicenter, open-label, single arm study of the safety and tolerability of Pirfenidone (ESBRIET) in combination with Nintedanib (OFEV) in patients with idiopathic pulmonary fibrosis
A study for patients with idiopathic pulmonary fibrosis using study drug Pirfenidone (ESBRIET) in combination with Nintedanib (OFEV)
Sponsor: Genentech
Enrolling: Male and Female Patients
IRB Number: AAAQ4059
Contact: Nina Patel: 212-305-1544 / np2199@cumc.columbia.edu
Additional Study Information: The purpose of this study is to investigate the safety of adding nentedanib to treatment with pifenidone in patients with Idiopathic Pulmonary Fibrosis (IPF). Eligible patients must be receiving consistent treatment with pifenidone for at least 16 weeks on a stable dose. Nintedanib will be added as an additional treatment for IPF (combination treatment) for 24 weeks. This is a phase IV, open-label, singlearmed trial. Participants will have center visits weekly for the first 4 weeks, and biweekly until 24 weeks.
This study is closed
Investigator
Nina Patel, MD
Do You Qualify?
Have you been diagnosed with idiopathic pulmonary fibrosis? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Nina Patel
np2199@cumc.columbia.edu
212-305-1544
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE